Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer : A Trial of the California, Chicago, and Princess Margaret Hospital Phase II ConsortiaGARCIA, Agustin A; HIRTE, Hal; SCUDDER, Sidney et al.Journal of clinical oncology. 2008, Vol 26, Num 1, pp 76-82, issn 0732-183X, 7 p.Article

Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumorsPIATEK, Caroline I; RAJA, Grace L; GARCIA, Agustin A et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 6, pp 1227-1234, issn 0344-5704, 8 p.Article

Clinical activity of pertuzumab (rhuMAb 2C4), a her dimerization inhibitor, in advanced ovarian cancer : Potential predictive relationship with tumor HER2 activation statusGORDON, Michael S; MATEI, Daniela; COHN, David E et al.Journal of clinical oncology. 2006, Vol 24, Num 26, pp 4324-4332, issn 0732-183X, 9 p.Article

Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin analysis of toxicities and predictors of outcomeSAFRA, Tamar; GROSHEN, Susan; JEFFERS, Susan et al.Cancer. 2001, Vol 91, Num 1, pp 90-100, issn 0008-543XArticle

Radical vaginal trachelectomy and pelvic lymphadenectomy for preservation of fertility in early cervical carcinomaBURNETT, Alexander F; ROMAN, Lynda D; O'MEARA, Anne T et al.Gynecologic oncology (Print). 2003, Vol 88, Num 3, pp 419-423, issn 0090-8258, 5 p.Article

Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix : A Gynecologic Oncology Group StudyMONK, Bradley J; SILL, Michael W; BURGER, Robert A et al.Journal of clinical oncology. 2009, Vol 27, Num 7, pp 1069-1074, issn 0732-183X, 6 p.Article